pyrroles has been researched along with imatinib mesylate in 317 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 110 (34.70) | 29.6817 |
| 2010's | 197 (62.15) | 24.3611 |
| 2020's | 10 (3.15) | 2.80 |
| Authors | Studies |
|---|---|
| Blanke, CD; Corless, CL; Druker, BJ; Heinrich, MC | 1 |
| Elcock, AH; Rockey, WM | 1 |
| Buchdunger, E; Fabbro, D; Forster, K; Hallek, M; Manley, PW; Mathes, R; Mitina, O; Moarefi, I; Simon, N; Warmuth, M | 1 |
| Garber, K | 1 |
| Abrams, TJ; Cherrington, JM; Lee, LB; Murray, LJ; Pryer, NK | 1 |
| Briesewitz, R; Bruner, RJ; Caligiuri, MA; Griffin, JH; Leung, J | 1 |
| Shiotsu, Y | 1 |
| Buchdunger, E; Fabbro, D; Hallek, M; Hu, Y; Li, S; Liu, Y; Pelletier, S; Van Etten, RA; Warmuth, M | 1 |
| Kobayashi, K | 1 |
| Fan, D; Fidler, IJ; He, J; Killion, JJ; Kim, SJ; Langley, RR; Tsan, R; Uehara, H; Yazici, S | 1 |
| Hanahan, D; Pietras, K | 1 |
| Advani, AS | 1 |
| Kwan, W; Liu, S; Lubieniecka, JM; Nielsen, TO; Terry, J | 1 |
| Cools, J; Debiec-Rychter, M; Folens, C; Marynen, P; Mentens, N; Prenen, H; Schöffski, P; Sciot, R; Van Oosterom, A | 1 |
| Borner, MM | 1 |
| Bertagnolli, MM; Demetri, GD; Desai, J; Fletcher, CD; George, S; Morgan, JA; Posner, M; Raut, CP; Zahrieh, D | 1 |
| de Groot, JW; Links, TP; van der Graaf, WT | 1 |
| Barone, A; Cherrington, JM; Laird, AD; Li, G; Mendel, DB; Moss, KG; Nannini, MA; Potapova, O | 1 |
| Campos, M; de Alava, E; Hernández, T; Mackintosh, C; Martín, DH; Martins, AS; Ordóñez, JL | 1 |
| Abruzzese, E; Amadori, S; Artico, M; Catalano, G; Cirilli, R; Ciriolo, MR; Di Stefano, C; Filomeni, G; La Regina, G; La Torre, F; Lavecchia, A; Marfè, G; Morgante, E; Morgante, M; Novellino, E; Russo, MA; Silvestri, R; Sinibaldi Salimei, P | 1 |
| Curtiss, FR | 1 |
| Blanke, CD; Schnadig, ID | 1 |
| Joensuu, H | 2 |
| Baum, CM; Bello, CL; Blackstein, ME; Casali, PG; Demetri, GD; Desai, J; Fletcher, CD; Garrett, CR; George, S; Heinrich, MC; Huang, X; Judson, IR; McArthur, G; Morgan, JA; Shah, MH; van Oosterom, AT; Verweij, J | 1 |
| Blanke, C | 2 |
| Denis, N; Dubreuil, P; Kosmider, O; Moreau-Gachelin, F | 1 |
| Campiani, G; Greene, LM; Kelly, L; Lawler, M; Onnis, V; Williams, DC; Zisterer, DM | 1 |
| Fletcher, JA; Rubin, BP | 1 |
| Abraham, S; Booth, BP; Chidambaram, N; Dagher, R; Gobburu, JV; Goodman, VL; Jiang, JX; Justice, R; Liang, CY; Mahjoob, K; Morse, DE; Pazdur, R; Ramchandani, RP; Rock, EP; Tang, S; Verbois, SL | 1 |
| Alberti, L; Blay, JY; Cassier, PA; Dufresne, A; Fayette, J; Ranchere, D; Ray-Coquard, I | 1 |
| von Mehren, M | 1 |
| Heldin, CH; Ostman, A | 1 |
| Maki, RG | 1 |
| Fletcher, CD; Hornick, JL | 1 |
| Baum, C; Beaudry, P; Bello, C; Demetri, GD; DePrimo, SE; Desai, J; Folkman, J; Force, J; Heymach, JV; Maki, R; Manola, J; Norden-Zfoni, A; Shalinsky, DR | 1 |
| Corless, CL; Heinrich, MC; Rubin, BP | 1 |
| Seynaeve, C; Sleijfer, S; Verweij, J; Wiemer, E | 1 |
| Siehl, J; Thiel, E | 1 |
| Benjamin, RS; Blanke, CD; Blay, JY; Casali, P; Choi, H; Corless, CL; Debiec-Rychter, M; DeMatteo, RP; Demetri, GD; Ettinger, DS; Fisher, GA; Fletcher, CD; Gronchi, A; Hohenberger, P; Hughes, M; Joensuu, H; Judson, I; Le Cesne, A; Maki, RG; Morse, M; Pappo, AS; Pisters, PW; Raut, CP; Reichardt, P; Tyler, DS; Van den Abbeele, AD; von Mehren, M; Wayne, JD; Zalcberg, J | 1 |
| Nishida, T | 1 |
| Bulusu, R; Carroll, N; Hatcher, H; Jessop, F; Judson, I; Murray, M; Williams, D | 1 |
| Demetri, G; Judson, I | 1 |
| Shen, L | 1 |
| Berets, O; Bladé, JS; Defuentes, G | 1 |
| Thomas, X | 1 |
| Faivre, S; Le Tourneau, C; Raymond, E | 1 |
| Corless, CL; Heinrich, MC | 1 |
| Dova, L; Fountzilas, G; Georgiou, I; Golfinopoulos, V; Malamou-Mitsi, V; Ntemou, A; Pavlidis, N; Pentheroudakis, G; Vartholomatos, G | 1 |
| Chen, J; Dong, S; Kang, S; Khoury, HJ; Lonial, S; Viallet, J | 1 |
| Astorino, M; Biasco, G; Brandi, G; Castellucci, P; Catena, F; Di Battista, M; Di Scioscio, V; Pantaleo, MA; Piazzi, G; Santini, D; Saponara, M | 1 |
| Bui, B; Italiano, A | 1 |
| Giordano, S; Petrelli, A | 1 |
| Debiec-Rychter, M; Dziewirski, W; Grzesiakowska, U; Michej, W; Nowecki, Z; Ruka, W; Rutkowski, P; Siedlecki, JA; Szawłowski, A | 1 |
| Kimura, S; Maekawa, T; Morinaga, K; Ueda, T; Yamauchi, T | 1 |
| Chevreau, C; Delord, JP; Deslandres, M; Sibaud, V | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
| Blackstein, ME; Chabot, I; LeLorier, J | 1 |
| Apice, G; Bruni, GS; Caponigro, F; Iaffaioli, RV; Milano, A | 1 |
| Agulnik, M; Aranha, O; Stein, E | 1 |
| Baker, SD; Dahl, GV; Hu, S; Inaba, H; Minkin, P; Niu, H; Orwick, S; Rubnitz, J; Shimada, A | 1 |
| Doi, T | 1 |
| Contreras-Hernández, I; Dávila-Loaiza, G; Garduño-Espinosa, J; Granados-García, V; Mould-Quevedo, JF; Petersen, JA; Salinas-Escudero, G; Silva, A; Villasís-Keever, MA | 1 |
| Hueman, MT; Schulick, RD | 1 |
| Balabanov, S; Bokemeyer, C; Brümmendorf, TH; Fiedler, W; Gontarewicz, A; Keller, G; Moll, J; Panse, J; Schafhausen, P | 1 |
| Rutkowski, P; Siedlecki, JA; Symonides, M; Zdzienicki, M | 1 |
| Eisenberg, B; Flieder, D; Godwin, AK; Koumbi, D; Merkel, E; Pathak, H; Rink, L; Tarn, C; Testa, JR; von Mehren, M | 1 |
| Corless, CL; Demetri, GD; Fletcher, CD; Fletcher, JA; Heinrich, MC; Kepten, I; Le, C; Liegl, B; Zhu, M | 1 |
| Dykens, JA; Hirakawa, B; Hynes, J; Jamieson, J; Jessen, BA; Marroquin, LD; Nadanaciva, S; Patyna, S; Will, Y | 1 |
| Caballero, G; de Alava, E; García-Sánchez, A; Herrero, D; Mackintosh, C; Madoz-Gúrpide, J; Martins, AS; Ordoñez, JL; Osuna, D; Otero, AP; Poremba, C; Sevillano, V | 1 |
| Reichardt, P | 3 |
| Hur, H; Jee, SB; Jeon, HM; Jung, SE; Kim, W; Park, AR | 1 |
| Bórquez Ma, P; Neveu C, R | 1 |
| Judson, IR | 1 |
| Antonescu, CR; Baum, CM; Cohen, DP; Corless, CL; Demetri, GD; Fletcher, CD; Fletcher, JA; Griffith, D; Harlow, A; Heinrich, MC; Huang, X; Maki, RG; McKinley, A; Ou, WB; Town, A | 1 |
| Ambudkar, SV; Bates, SE; Robey, RW; Shukla, S | 1 |
| Alberti, L; Arifi, S; Blay, JY; Bringuier, PP; Cassier, PA; Dufresne, A; El Sayadi, H; Ray-Coquard, I; Scoazec, JY | 1 |
| Bluestone, JA; Bollag, G; Lang, J; Lee, MR; Louvet, C; Martinier, N; Szot, GL; Weiss, A; Zhu, S | 1 |
| Iwata, C; Kano, MR; Kataoka, K; Komuta, Y; Miyazono, K; Morishita, Y; Oka, M; Ouchi, Y; Shirai, YT | 1 |
| Loong, HH; Yeo, W | 1 |
| Benhattar, J; Delaloye, AB; Elsig, V; Guillou, L; Leyvraz, S; Luthi, F; Michielin, O; Montemurro, M; Orcurto, MV; Prior, JO; Stupp, R | 1 |
| Brosa, M; Díaz, S; García del Muro, X; González, P; Grande, E; Paz-Ares, L | 1 |
| Christensen, J; Demetri, GD; Deshmukh, GD; Diehl, W; DiNitto, JP; Emmett, MR; English, JM; Gajiwala, KS; Greig, MJ; He, YA; Jacques, SL; Lunney, EA; Marshall, AG; McTigue, M; Molina, D; Quenzer, T; Wells, PA; Wu, JC; Yu, X; Zhang, HM; Zhang, Y; Zou, A | 1 |
| Bernstein, ML | 1 |
| Sevinc, A | 1 |
| Blay, JY; Casali, PG; Cohen, DP; Demetri, GD; Deprimo, SE; George, S; Harmon, CS; Law, CN; Le Cesne, A; Morgan, JA; Ray-Coquard, I; Stephenson, P; Tassell, V | 1 |
| Blanke, CD; Fernandes, Gdos S; Freitas, D; Guedes, R; Hoff, PM | 1 |
| von Mehren, M; Watson, JC | 1 |
| Bertagnolli, MM; Raut, CP | 1 |
| Albritton, KH; Butrynski, JE; D'Amato, GZ; Demetri, GD; Heinrich, MC; Janeway, KA; Pedrazzoli, P; Picus, J; Schlemmer, M; Siena, S; Van Den Abbeele, AD | 1 |
| Ahlman, H; Nilsson, B; Nilsson, O | 1 |
| Clohisy, DR; Frolich, JW; Manivel, JC; Skubitz, KM | 1 |
| Blay, JY | 2 |
| Gelderblom, H; Grünwald, V; Hartmann, JT; Joensuu, H; Leyvraz, S; Montemurro, M; Reichardt, P; Roth, A; Schöffski, P; Schütte, J; Seddon, B; von Moos, R; Weber, E; Wendtner, CM | 1 |
| Bovée, JV; Gelderblom, H; Hogendoorn, PC; Kroep, JR; van der Molen, AJ | 1 |
| Blay, JY; Reichardt, P | 1 |
| Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B | 1 |
| Akyurek, N; Benekli, M; Buyukberber, S; Coskun, U; Demirci, U; Karakan, T; Tonyali, O; Yildiz, R | 1 |
| Di Stefano, C; Marfe, G | 1 |
| Eisterer, W; Ploner, F | 1 |
| Schiff, D; van den Bent, MJ; Wen, PY | 1 |
| Becker, CR; Berger, F; Nikolaou, K; Reiser, MF; Schinwald, N; Schlemmer, M; Sourbron, SP | 1 |
| Doi, T; Komatsu, Y; Li, Y; Muro, K; Nishida, T; Ohtsu, A; Shirao, K; Ueda, E | 1 |
| Gelderblom, H; Guchelaar, HJ; van Erp, NP | 1 |
| Antonescu, CR; Baum, CM; Bello, CL; Chen, MH; Cohen, DP; Corless, CL; Demetri, GD; Fletcher, CD; Fletcher, JA; George, S; Heinrich, MC; Huang, X; Maki, RG; Morgan, JA; Van den Abbeele, AD | 1 |
| Baum, CM; Blackstein, ME; Demetri, GD; Deprimo, SE; Garrett, CR; Harmon, CS; Huang, X; Schöffski, P; Shah, MH; Verweij, J | 1 |
| Kang, DY; Kim, S; Lee, HJ; Lim, JS; Song, IC; Yun, HJ | 1 |
| D'Adamo, D | 1 |
| Schöffski, P; Wolter, P | 1 |
| Biasco, G; Catena, F; Di Battista, M; Nannini, M; Pantaleo, MA | 1 |
| Hohenberger, P | 1 |
| Agaimy, A; Schneider-Stock, R | 1 |
| Briaire-de Bruijn, IH; Gelderblom, H; Hogendoorn, PC; Jordanova, ES; Ottenhoff, TH; Savage, ND; van der Burg, SH; van Dongen, M; van Hall, T; Walburg, KV | 1 |
| Wang, ZY | 1 |
| De Greve, J; Decoster, L; Fontaine, C; Schallier, D; Trullemans, F | 1 |
| Miyazaki, Y; Nishida, T; Takahashi, T | 1 |
| Patel, SR; Pisters, PW | 1 |
| Diehl, W; Emmett, MR; Gajiwala, KS; Greig, MJ; Lunney, EA; Marshall, AG; Wu, JC; Yu, X; Zhang, HM | 1 |
| Coli, R; Deshmukh, GD; Diehl, W; DiNitto, JP; English, JM; Jacques, SL; Worrall, JW; Wu, JC; Zhang, Y | 1 |
| Ashman, LK; Griffith, R; Mashkani, B | 1 |
| Bright, SA; Campiani, G; Deininger, MW; Lawler, M; Williams, DC; Zisterer, DM | 1 |
| Blay, JY; Cassier, PA | 1 |
| Antonescu, CR; DeMatteo, RP; Demetri, GD; Ganjoo, KN; Maki, RG; Pisters, PW; Raut, CP; Riedel, RF; Schuetze, S; Sundar, HM; Trent, JC; von Mehren, M; Wayne, JD | 1 |
| Bonvalot, S; Cioffi, A; Dômont, J; Le Cesne, A; Tardieu, M | 1 |
| Ahlman, H; Andersson, A; Nilsson, B; Nilsson, E; Nilsson, O; Sjölund, K | 1 |
| Bayraktar, S; Bayraktar, UD; Rocha-Lima, CM | 1 |
| Saijo, N | 1 |
| Benekli, M; Bilge Yilmaz, I; Buyukberber, S; Coskun, U; Demirci, U; Erdem, O; Ozturk, B | 1 |
| Cai, SR; Chen, CQ; Chen, JH; He, YL; Ma, JP; Wu, KM; Zhan, WH; Zhang, XH | 1 |
| Agostino, NM; Chinchilli, VM; Drabick, JJ; Gingrich, R; Koszyk-Szewczyk, A; Lynch, CJ; Sivik, J | 1 |
| Al-Sarraf, R; Johnson, CS; Malone, EK; Rassnick, KM; Ruslander, DM; Russell, DS; Trump, DL; Wakshlag, JJ | 1 |
| Hara, K; Hijioka, S; Kawai, H; Kondo, S; Matsumoto, K; Mizuno, N; Niwa, Y; Sawaki, A; Tajika, M; Yamao, K | 1 |
| Bauer, S; Grabellus, F; Schmid, KW; Sheu, SY; Speich, N; Worm, K | 1 |
| Delank, S; Eich, H; Wendtner, CM | 1 |
| Beck, MY; Chang, HM; Choi, DR; Kang, YK; Kim, KP; Kim, TW; Lee, JL; Ryoo, BY; Ryu, MH; Yoo, C | 1 |
| Liang, ZY | 1 |
| Blanke, CD; Huse, DM | 1 |
| Beck, M; Chang, HM; Cho, Y; Choi, DR; Kang, YK; Kim, TW; Lee, JL; Ryoo, BY; Ryu, MH; Yoon, DH | 1 |
| Alacacioglu, A; Camci, C; Dikilitas, M; Er, O; Kalender, ME; Sagol, O; Sari, I; Sevinc, A; Soyuer, I; Yilmaz, U | 1 |
| Chu, DT | 1 |
| Conley, A; George, S; Lazar, AJ; Nolden, L; Reynoso, D; Trent, JC; Wang, WL | 1 |
| Blay, JY; Coscas, Y; Khayat, D; Pivot, X; Soria, JC; Spano, JP | 1 |
| Ganjoo, KN; Patel, S | 1 |
| Cano Megías, M; Carrasco De La Fuente, M; González Albarrán, O; Menacho Román, M; Pérez López, G | 1 |
| Diebold, J; Hirschmann, A; Rössle, M | 1 |
| Raut, CP; Winer, JH | 1 |
| Kamiya, K; Kikuchi, H; Konno, H; Miyazaki, S; Ohta, M; Sakaguchi, T; Setoguchi, T; Yamamoto, M | 1 |
| Hanazaki, K; Ikezoe, T; Nishioka, C; Taguchi, T; Takezaki, Y; Yang, J; Yokoyama, A | 1 |
| Doi, T; Kakeji, Y; Kanda, T; Komatsu, Y; Nishida, T; Ohtsu, A; Onozawa, Y; Sawaki, A; Yamada, Y; Yamasaki, M | 1 |
| Blanke, CD; Picus, J; Pisters, PWT; Sirulnik, A; Stealey, E; Trent, JC; von Mehren, M | 1 |
| Bauer, S; Montemurro, M | 1 |
| DiNitto, JP; Wu, JC | 1 |
| Aglietta, M; Bono, P; Boselli, S; Casali, PG; Coco, P; De Braud, F; De Pas, T; Grignagni, G; Jalava, T; Joensuu, H; Kappeler, C; Laurent, D; Spitalieri, G; Spreafico, C; Toffalorio, F | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Nishida, T; Omori, T; Ueshima, S | 1 |
| Akimoto, H; Chinen, Y; Kawano, H; Kojo, M; Minami, K; Morita, K; Okamura, T; Saeki, H; Sakaguchi, Y; Sakamoto, Y; Soejima, Y; Sugiyama, M; Toh, Y | 1 |
| Lewis, VO; Ravi, V; Wang, WL | 1 |
| Geoerger, B; Leblond, P | 1 |
| Blay, JY; Chaigneau, L; Curtit, E; Dobi, E; Kalbacher, E; Mansi, L; Nguyen, T; Pivot, X; Viel, E | 1 |
| Hatakeyama, K; Ishikawa, T; Kanda, T; Kosugi, S; Yajima, K | 1 |
| Debiec-Rychter, M; Faa, G; Floris, G; Normant, E; Schöffski, P; Sciot, R; Van Looy, T; Wellens, J; Wozniak, A | 1 |
| Cunningham, D; Yim, KL | 1 |
| Debiec-Rychter, M; Faa, G; Floris, G; Machiels, K; Normant, E; Schöffski, P; Sciot, R; Stefan, C; Vanleeuw, U; Wozniak, A | 1 |
| Reichardt, A; Reichardt, P | 1 |
| Akita, K; Fujii, I; Gouda, M; Ishihama, Y; Kirii, Y; Kitagawa, D; Narumi, Y; Sugiyama, N; Yokota, K | 1 |
| Patil, DT; Rubin, BP | 1 |
| Elders, A; Fraser, C; Hislop, J; Jenkinson, D; Mowatt, G; Petty, R; Sharma, P; Vale, L | 1 |
| Antonescu, C | 1 |
| Akkus, M; Baykara, M; Benekli, M; Buyukberber, S; Coskun, U; Dane, F; Dursun, A; Gonul, II; Sevinc, A; Yildiz, R | 1 |
| Braun, D; Hershman, JM; Kim, TD; Köhrle, J; le Coutre, P; Schweizer, U | 1 |
| Patel, S | 1 |
| Adenis, A; Antonescu, CR; Blay, JY; Bompas, E; Bui, B; Casali, P; Cioffi, A; Coco, P; Coindre, JM; Debiec-Rychter, M; Duffaud, F; Isambert, N; Italiano, A; Keohan, ML; Le Cesne, A; Maki, RG; Rutkowski, P; Schöffski, P; Toulmonde, M | 1 |
| Caram, MV; Schuetze, SM | 1 |
| Kim, EJ; Zalupski, MM | 1 |
| Bennett, JJ; Rubino, MS | 1 |
| Bove, B; Cauchi, C; Davey, M; Engstrom, PF; Lee, J; Litwin, S; Lopez, M; Somaiah, N; von Mehren, M | 1 |
| Ashley, SW; Grover, S; Raut, CP | 1 |
| Chika, N; Kakimoto, M; Kikuchi, A; Koshiishi, H; Nishida, K; Okamura, T; Tokita, H; Yoshimura, T | 1 |
| Hazama, S; Inoue, Y; Oka, M; Suzuki, N; Yoshino, S | 1 |
| Brentani, RR; Cooke, VG; Damascena, A; Duncan, MB; Kalluri, R; Keskin, D; Khan, Z; LeBleu, VS; Maeda, G; O'Connell, JT; Rocha, RM; Sugimoto, H; Teng, Y; Vong, S; Xie, L | 1 |
| Buti, S; Buttitta, F; Calabrese, F; Cavazza, A; Di Chiara, F; Felicioni, L; Garagnani, L; Marchetti, A; Mengoli, MC; Migaldi, M; Nannini, N; Nicoli, D; Rea, F; Rossi, G; Sartori, G; Schirosi, L; Valli, R | 1 |
| Blay, JY; Bui-Nguyen, B; Demetri, GD; Galetic, I; Gelderblom, H; Hsu, Y; McArthur, GA; Reichardt, P; Rutkowski, P; Schlemmer, M; Yazji, S | 1 |
| George, S; Hornick, JL; Jagannathan, JP; Ramaiya, NH; Shinagare, AB | 1 |
| Agulnik, M; Huyck, TK; Svetlichnaya, J; Wayne, JD | 1 |
| Brzeskwiniewicz, M; Bylina, E; Falkowski, S; Grzesiakowska, U; Klimczak, A; Kroc, J; Limon, J; Lugowska, I; Melerowicz, W; Mierzejewska, E; Nowecki, ZI; Osuch, C; Rutkowski, P; Siedlecki, JA; Switaj, T; Wasielewski, K; Woźniak, A | 1 |
| Lu, W; Lu, WQ | 1 |
| Bos, WE; de Jonge, MJ; Hamberg, AP; Nijsten, TE | 1 |
| Koshenkov, VP; Rodgers, SE | 1 |
| Chung, AS; Ferrara, N; Finkle, D; Komuves, L; Kowanetz, M; Ngu, H; Peale, F; Wu, X; Zhuang, G | 1 |
| Butrynski, JE; Choy, E; Corless, CL; Demetri, GD; Fletcher, JA; George, S; Heinrich, MC; Manola, JB; Morgan, JA; Solomon, SM; Tap, WD; Van den Abbeele, AD; von Mehren, M; Wagner, AJ; Wang, Q; Yap, JT; Zhu, M | 1 |
| Lai, EC; Lau, SH; Lau, WY | 1 |
| Gao, J; Hong, J; Li, J; Shen, L | 1 |
| Blay, JY; Casali, PG; Cohen, DP; Demetri, GD; Garrett, CR; Goldstein, D; Harmon, CS; Huang, X; Hurwitz, HI; Le Cesne, A; Leyvraz, S; McArthur, GA; Paz-Ares, L; Pousa, AL; Schöffski, P; Shah, MH; Tassell, V; Verweij, J; Xu, QC | 1 |
| Bonenkamp, JJ; de Wilt, JH; Gelderblom, H; Hartgrink, HH; Sleijfer, S; Tielen, R; van Coevorden, F; van der Graaf, WT; Verhoef, C | 1 |
| Athanasou, NA; Bradley, KM; Dijkstra, PD; Gelderblom, H; Gibbons, CL; Hassan, AB; Hogendoorn, PC; Kroep, JR; Nout, RA; van de Sande, MA; van der Heijden, L; van Rijswijk, CS | 1 |
| Donohue, JH; Nagorney, DM; Okuno, SH; Que, FG; Zaydfudim, V | 1 |
| Airley, R | 1 |
| Cohen, DP; Demetri, GD; George, S; Lechner, T; Li, S; Reichardt, P | 1 |
| Gallowitsch, HJ; Malle, P; Sorschag, M | 1 |
| Balakrishnar, B; Clements, A; Gao, B; Gurney, H; Wong, M; Yeap, S | 1 |
| Hong, JL; Li, J; Shen, L | 1 |
| Nishida, T; Ueshima, S; Wakasugi, M | 1 |
| Beach, S; Bonneau, O; Burton, V; Ciuclan, L; Clay, I; Duggan, N; Fox, R; Good, R; Hussey, MJ; Jarai, G; Jones, P; Konstantinova, I; MacLean, MR; Pearce, A; Rowlands, DJ; Thomas, M; Westwick, J | 1 |
| Bauer, S; Bitz, U; Blay, JY; Duffaud, F; Gelderblom, H; Joensuu, H; Montemurro, M; Pink, D; Rutkowski, P; Schütte, J; Trent, J | 1 |
| Badalamenti, G; Bauer, S; Blackstein, M; Blay, JY; Casali, PG; Chung, J; Demetri, GD; Gelderblom, H; Hohenberger, P; Joensuu, H; Kang, YK; Kappeler, C; Kuss, I; Laurent, D; Le Cesne, A; Leahy, M; Maki, RG; Nguyen, BB; Nishida, T; Reichardt, P; Rutkowski, P; Schöffski, P; von Mehren, M; Xu, J | 1 |
| Cunningham, D; Waddell, T | 1 |
| Matsui, K; Moriyama, M; Nagata, T; Okumura, T; Omura, T; Sawada, S; Sekine, S; Shimada, Y; Tsukada, K; Yoshida, T; Yoshioka, I | 1 |
| Funaki, H; Kaida, D; Kinami, S; Kosaka, T; Minato, H; Morioka, E; Nakano, Y; Nakata, S; Noguchi, M; Ohnishi, T; Ohno, Y; Omote, K; Takamura, H; Tomita, Y; Ueda, N | 1 |
| Godwin, AK; Ochs, MF; Rink, L; von Mehren, M; Zhou, Y | 1 |
| Buti, S; Donini, M; Passalacqua, R; Rossi, G; Rossi, V; Sergio, P | 1 |
| Gao, J; Li, J; Shen, L; Sun, N; Tian, Y; Yuan, J | 1 |
| Al-Amin, A; Fred, RG; Idevall-Hagren, O; Li, J; Li, T; Mokhtari, D; Ravassard, P; Scharfmann, R; Tengholm, A; Turpaev, K; Welsh, N; Wuttke, A | 1 |
| Ba-Ssalamah, A; Bareck, E; Brodowicz, T; Eisterer, W; Häfner, M; Högenauer, C; Kastner, U; Kühr, T; Längle, F; Liegl-Atzwanger, B; Ploner, F; Schoppmann, SF; Widmann, G; Wrba, F; Zacherl, J | 1 |
| Nishida, T; Tori, M; Yoshidome, K | 1 |
| Chen, ZF; Chi, P; Guan, GX; Jiang, WZ; Liu, X; Lu, HS | 1 |
| Cao, H; Xu, J | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Robert, C; Sibaud, V | 1 |
| Chen, LT; Chen, TS; Chiang, NJ; Hsueh, YS; Ko, CH; Li, CF; Lin, CL; Shan, YS; Shih, NY; Wang, LM; Yen, CC | 1 |
| De Giorgi, U | 1 |
| Carducci, MA; Fu, C; Gerber, S; Hammers, HJ; Kachhap, S; No, E; Sheibani, N; Van Den Berg, S; van der Zwan, A; Wang, WC | 1 |
| Aboagye, EO; Ashek, A; Barnes, G; Cotroneo, E; Cupitt, J; Dabral, S; Dubois, O; El-Bahrawy, MA; Fang, W; Gibbs, JS; Gsell, W; He, JG; Howard, LS; Jones, H; Nguyen, QD; Pullamsetti, SS; Tomasi, G; Wang, L; Wilkins, MR; Zhao, L | 1 |
| Akça, Z; Büyükçelik, A; Kaya, N; Mutlu, H | 1 |
| Lyseng-Williamson, KA | 1 |
| Choi, YJ; Jo, J; Kang, YK; Lee, JJ; Park, I; Park, JH; Ryoo, BY; Ryu, JS; Ryu, MH; Tan, E; Yoo, C | 1 |
| Ding, JF; Zhong, DF | 1 |
| Demetri, GD; Jagannathan, J; Kang, YK; Kim, HJ; Lee, JJ; Nam, BH; Ramaiya, N; Ryoo, BY; Ryu, MH; Yoo, C | 1 |
| Doi, T; Nishida, T | 1 |
| Bonkovsky, HL; Hwang, SI; Lee, JG; McKinney, KQ; Mougeot, JL | 1 |
| Jin, L; Kong, X; Lou, L; Quan, H; Xu, Y; Zhao, J | 1 |
| Beijnen, JH; Huitema, AD; Knapen, LM; Lankheet, NA; Schellens, JH; Steeghs, N | 1 |
| Akahoshi, S; Inoue, K; Kiyota, Y; Kiyozumi, Y; Motooka, Y; Yamaguchi, R; Yoshida, Y | 1 |
| Butrynski, JE; D'Adamo, D; Demetri, GD; Fisher, GA; Ganjoo, KN; George, S; Kamaya, A; McMillan, A; Morgan, JA; Villalobos, VM; Wagner, AJ | 1 |
| Choy, E; Demetri, GD; George, S; Jagannathan, JP; Kurra, V; Manola, J; Ramaiya, NH; Shinagare, AB; Urban, T | 1 |
| El-Gamal, MI; Oh, CH | 1 |
| Behera, R; Mensa-Wilmot, K; Thomas, SM | 1 |
| Antonescu, CR; Besmer, P; Cavnar, MJ; Cohen, NA; Crawley, MH; Dematteo, RP; Green, BL; Greer, JB; Kim, TS; Ku, AT; Pillarsetty, N; Popow, R; Rossi, F; Seifert, AM; Sorenson, EC; Veach, DR; Zeng, S | 1 |
| Beckman, MJ; de Stanchina, E; Dematteo, RP; Patwardhan, PP; Schwartz, GK; Surriga, O; Tap, WD | 1 |
| Cooper, ZA; Ferrone, CR; Ferrone, S; Flaherty, KT; Frederick, DT; Kirkwood, JM; Pepe, S; Pepin, D; Sabbatino, F; Scognamiglio, G; Wang, X; Wang, Y; Wargo, JA; Yu, L | 1 |
| Liang, H | 1 |
| Liang, X; Shi, Y | 1 |
| Beaune, P; de Waziers, I; Favre, A; Figg, WD; Kiehl, P; McMullen, J; Montemurro, M; Narjoz, C; Rochat, B | 1 |
| Boralevi, F; Fricain, JC; Sibaud, V; Vigarios, E | 1 |
| Ashman, P; Cid Ruzafa, J; Desai, K; Khalid, JM; Maguire, A; Muston, D; Starczewska Amelio, JM; Tzivelekis, S | 1 |
| Benjamin, RS; Bergman, MA; Boles, S; Bui, MM; Casper, ES; Conrad, EU; DeLaney, TF; Ganjoo, KN; George, S; Gonzalez, RJ; Heslin, MJ; Kane, JM; Mayerson, J; McGarry, SV; Meyer, C; O'Donnell, RJ; Pappo, AS; Paz, IB; Pfeifer, JD; Randall, RL; Riedel, RF; Schuetze, S; Schupak, KD; Schwartz, HS; Sundar, H; Van Tine, BA; von Mehren, M; Wayne, JD | 1 |
| Chang, J; Connolly, MP; Currie, CJ; Poole, CD | 1 |
| Doi, T; Naito, Y; Nishida, T | 1 |
| Acin, Y; Adenis, A; Bertucci, F; Blay, JY; Blésius, A; Bompas, E; Bouché, O; Bui-Nguyen, B; Bulusu, VR; Chaigneau, L; Domont, J; Dubreuil, P; Hermine, O; Isambert, N; Le Cesne, A; Mansfield, CD; Moussy, A; Ray-Coquard, I; Van Tine, BA | 1 |
| Chen, JS; Chen, TW; Chen, YY; Cheng, CT; Chiang, KC; Hsu, CC; Jan, YY; Liu, YY; Tsai, CY; Tseng, JH; Wu, CE; Yeh, CN; Yeh, TS | 1 |
| Anjum, R; Bauer, S; Clackson, T; Eilers, G; Fletcher, JA; Garner, AP; Gozgit, JM; Heinrich, MC; Ketzer, J; Kohlmann, A; Ning, Y; Rivera, VM; Schrock, A; Serrano, C; Song, Y; Vodala, S; Wang, F; Wardwell, S; Zhou, T; Zhu, M | 1 |
| Alago, W; Brown, KT; Cornelis, F; Covey, A; Erinjeri, JP; Getrajdman, GI; Litchman, T; Maybody, M; Sofocleous, CT; Solomon, SB; Takaki, H | 1 |
| Liu, K; Wen, Y; Wu, L; Xiong, L; Yao, H; Zhang, Z | 1 |
| Schmutz, JL | 1 |
| Blay, JY; Cassier, P; Dufresne, A; Heudel, P; Pissaloux, D; Ray-Coquard, I; Wang, Q | 1 |
| Boglione, A; Comandone, A | 1 |
| Demetri, GD; Doi, T; Kanda, T; Komatsu, Y; Kuss, I; Nishida, T; Sawaki, A; Yamada, Y | 1 |
| Egawa, C; Goto, T; Hashimoto, T; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Kimura, K; Kuroda, Y; Kusama, H; Matsushita, K; Morimoto, Y; Nakahira, S; Nakatsuka, S; Nitta, K; Ohmura, Y; Ohzono, K; Okishiro, M; Sakisaka, H; Sato, Y; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H | 1 |
| Hosaka, S; Kawamoto, S; Kikutake, T; Nagao, S; Umemoto, S; Yonemitsu, K; Yoshida, T | 1 |
| Lin, XK; Liu, XS; Shou, CH; Sun, JY; Yang, WL; Yu, JR; Zhang, Q | 1 |
| Bencsikova, B; Bortlicek, Z; Brabec, P; Jureckova, A; Kocak, I; Kocakova, I; Krejci, E; Spelda, S; Strenkova, J; Vyzula, R | 1 |
| Antonescu, CR; Beckman, MJ; Besmer, P; Cohen, NA; Crawley, MH; DeMatteo, RP; Green, BL; Greer, JB; Kim, TS; Rossi, F; Santamaria-Barria, JA; Seifert, AM; Sorenson, EC; Zeng, S | 1 |
| Bekerman, E; Einav, S | 1 |
| Pilotte, AP | 1 |
| Bobrzyk, M; Chronowska, J; Kukla, U; Madej, P; Okopień, B; Łabuzek, K | 1 |
| He, Y; Zhang, X | 1 |
| Boccardi, V; Marano, L; Marrelli, D; Roviello, F | 1 |
| Baldini, C; Bridal, SL; Comperat, E; Dizeux, A; Lamuraglia, M; Le Guillou-Buffello, D; Lucidarme, O; Payen, T | 1 |
| Kato, S | 1 |
| Badalamenti, G; Bronte, G; Casali, P; De Lisi, D; Dei Tos, AP; Frezza, AM; Fumagalli, E; Nannini, M; Pantaleo, MA; Russo, A; Santini, D; Spalato Ceruso, M; Tonini, G; Vincenzi, B | 1 |
| Bauer, S; Bright, SA; Butini, S; Campiani, G; Greene, LM; Kinsella, P; Pollock, JK; Williams, DC; Zisterer, DM | 1 |
| Eckstein, N; Frötschl, R; Haas, B; Weber-Lassalle, K | 1 |
| Ando, T; Hosokawa, A; Kajiura, S; Nakada, N; Nanjyo, S; Sugiyama, T | 1 |
| Adenis, A; Bertucci, F; Blay, JY; Bompas, E; Bouché, O; Cassier, P; Cesne, AL; Chauzit, E; Cropet, C; Duffaud, F; Gautier, J; Isambert, N; Italiano, A; Mir, O; Molimard, M; Pérol, D; Ray-Coquard, I; Rios, M; Toulmonde, M | 1 |
| Barysauskas, CM; Ben-Ami, E; Butrynski, JE; Choy, E; Corless, CL; Demetri, GD; Fletcher, JA; George, S; Heinrich, MC; Morgan, JA; Solomon, SM; Van den Abbeele, AD; von Mehren, M; Wagner, AJ; Yap, JT | 1 |
| Im, SA; Kang, YK; Kim, TY; Lee, SJ; Park, JO; Park, SR; Ryoo, BY; Ryu, MH; Son, MK | 1 |
| Maki, RG; Martínez-Marín, V | 1 |
| Angenendt, P; Diehl, F; Fredebohm, J; Holtrup, F; Löber, AK; Mehnert, DH; van Rahden, V | 1 |
| Ha, HK; Kim, AY; Kim, HJ; Kim, JS; Lee, JS; Park, SH | 1 |
| Angelini, S; Biasco, G; Gatto, L; Hrelia, P; Nannini, M; Pantaleo, MA; Ravegnini, G; Sammarini, G; Saponara, M; Simeon, V; Urbini, M; Venturoli, N; Zenesini, C | 1 |
| Chen, T; Chen, Z; Feng, X; Li, G; Li, Y; Qiu, H; Sun, X; Tao, K; Yu, J; Zhang, P; Zhou, Z | 1 |
| Azouz, MM; Bouassida, M; Chelbi, E; El Bouchtili, S; Ezzine, H; Hamzaoui, L; Mahmoudi, M; Medhioub, M; Touinsi, H | 1 |
| Bonsignore, R; Gentile, C; Lauria, A; Martorana, A | 1 |
| Kubo, N; Takeuchi, N | 1 |
| Cubedo, R; García Del Muro, X; López-Guerrero, JA; Martín-Broto, J; Martínez, V; Poveda, A; Romero, I; Serrano, C; Valverde, C | 1 |
| Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Bonneville-Levard, A; Chauffert, B; Chevreau, C; Cupissol, D; Duffaud, F; Fabbro, M; Feuvret, L; Le Cesne, A; Lebellec, L; Mir, O; Noel, G; Penel, N; Saada-Bouzid, E; Vauleon, E; Vinceneux, A | 1 |
| Chen, X; Cheng, Y; Cui, Z; Jia, S; Liang, S; Shen, T; Si, G; Song, S; Yu, H; Yu, X; Zhang, J; Zhang, X | 1 |
| Burger, DM; Desar, IME; Kweekel, DM; Lankheet, NAG; Mulder, SF; van der Graaf, WTA; van Erp, NP; van Herpen, CML | 1 |
| Higuchi, M; Hikasa, Y; Leong, ZP; Okida, A; Yamano, Y | 1 |
| Benson, C; Chou, AJ; Magnan, H; Rutkowski, P | 1 |
| Jiang, T; Piao, D; Wang, W; Zhang, Z | 1 |
| Filip-Psurska, B; Kutner, A; Maj, E; Milczarek, M; Psurski, M; Wietrzyk, J | 1 |
| Doki, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Saito, Y; Takahashi, T; Takiguchi, S; Tanaka, K; Yamasaki, M | 1 |
| Aoyama, T; Cho, H; Hayashi, T; Kano, K; Maezawa, Y; Masuda, M; Ogata, T; Oshima, T; Rino, Y; Sato, T; Yamada, T; Yoshikawa, T; Yukawa, N | 1 |
| Sendo, T; Shimada, A; Yagi, K | 1 |
| Ishigame, T; Kase, K; Kenjo, A; Kimura, T; Kofunato, Y; Marubashi, S; Muto, M; Okada, R; Sato, N; Shimura, T; Watanabe, J | 1 |
| Gong, JF; Ji, JF; Li, J; Li, XT; Li, ZY; Shen, L; Sun, YS; Tang, L | 1 |
| Aka, Y; Bakar-Ates, F; Kilic-Kurt, Z; Kutuk, O | 1 |
| Boichuk, S; Dunaev, P; Galembikova, A; Khromova, N; Kopnin, P; Micheeva, E; Novikova, M | 1 |
| Brzozowska, M; Czech, M; Potemski, P; Połowinczak-Przybyłek, J; Śliwczyński, A; Szafraniec-Buryło, S; Wierzba, W | 1 |
| Abe, A; Hayakawa, F; Ichihara, M; Inoue, C; Kawamoto, Y; Murate, T; Nishizawa, Y; Nozawa, Y; Sobue, S; Suzuki, M | 1 |
| Gennatas, S; Huang, P; Jones, RL; Smrke, A | 1 |
| George, S; Serrano, C | 1 |
| Dong, Z; Li, J | 1 |
| Cao, X; Huang, H; Lei, X; Liu, J; Peng, J; Tang, G; Zhang, Y | 1 |
| Gomes, A; Mankoski, R; Miller, A; Nellesen, D; Norregaard, C; Proudman, D; Sullivan, E | 1 |
| Doi, T; Honma, Y; Iwagami, S; Komatsu, Y; Kurokawa, Y; Naito, Y; Nishida, T; Sawaki, A; Takahashi, T | 1 |
| Bond, J; Ellison-Hughes, GM; Lewis-McDougall, FC; Ruchaya, P; Smith, AJ; Walmsley, R; Wright, KE | 1 |
| Hirota, S; Ishikawa, T; Kanda, T; Matsumoto, Y; Saijo, Y; Sasaki, K | 1 |
| Hu, K; Shu, M; Wang, X; Zhang, H | 1 |
104 review(s) available for pyrroles and imatinib mesylate
| Article | Year |
|---|---|
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.
Topics: Angiogenesis Inhibitors; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasms; Oxindoles; Piperazines; Propionates; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles | 2002 |
[Current screening for molecular target therapy of cancer].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib | 2003 |
[Lung cancer: molecular targeting therapy].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gene Targeting; Genetic Therapy; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Piperazines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Trastuzumab | 2004 |
C-kit as a target in the treatment of acute myelogenous leukemia.
Topics: Acute Disease; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Clinical Trials as Topic; Hematopoiesis; Humans; Imatinib Mesylate; Indoles; Leukemia, Myeloid; Mice; Oxindoles; Piperazines; Propionates; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Stem Cell Factor | 2005 |
[Molecular targets in colon cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib | 2006 |
Gastrointestinal stromal tumors: imatinib and beyond.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2006 |
KIT mutations in GIST.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Models, Biological; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Sunitinib | 2007 |
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Renal Cell; Drug Approval; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kidney Neoplasms; Piperazines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; United States; United States Food and Drug Administration | 2007 |
Emerging drugs for the treatment of soft tissue sarcomas.
Topics: Antineoplastic Agents; Benzamides; Dacarbazine; Doxorubicin; Gastrointestinal Stromal Tumors; Humans; Ifosfamide; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sarcoma; Sunitinib | 2007 |
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Niacinamide; Oligonucleotides; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sirolimus; Staurosporine; Sunitinib; Thiazoles | 2006 |
PDGF receptors as targets in tumor treatment.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Extracellular Fluid; Fibroblasts; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Pressure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Sunitinib; Translocation, Genetic | 2007 |
Recent advances in therapy for gastrointestinal stromal tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2007 |
The role of KIT in the management of patients with gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2007 |
Gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Biology; Piperazines; Positron-Emission Tomography; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sunitinib | 2007 |
Second line therapies for the treatment of gastrointestinal stromal tumor.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Treatment Failure | 2007 |
C-kit, GIST, and imatinib.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2007 |
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
Topics: Advisory Committees; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Piperazines; Practice Guidelines as Topic; Prognosis; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed; United States | 2007 |
Advances in the treatment of gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2007 |
[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzenesulfonates; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2007 |
New developments in multitargeted therapy for patients with solid tumours.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2008 |
Molecular pathobiology of gastrointestinal stromal sarcomas.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sarcoma; Sunitinib | 2008 |
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles | 2008 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
[Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2008 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Dioxoles; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Niacinamide; Oligonucleotides; Phthalazines; Piperazines; Proto-Oncogene Mas; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Tetrahydroisoquinolines; Trabectedin | 2006 |
New therapeutic options in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2008 |
[GIST].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2008 |
Management of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Esophageal Neoplasms; Esophagectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Pyrroles; Risk Assessment; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Developments in targeted therapy of advanced gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2008 |
Novel approaches to imatinib- and sunitinib-resistant GIST.
Topics: Angiogenesis Inhibitors; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2008 |
[Gastrointestinal stromal tumors. An update].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2008 |
Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib | 2008 |
Perioperative treatment of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoadjuvant Therapy; Pharmacogenetics; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2009 |
Treatment of gastrointestinal stromal tumours: imatinib, sunitinib -- and then?
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Design; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib | 2009 |
Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Female; Fibromatosis, Aggressive; Follow-Up Studies; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2009 |
Extra-abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Carcinoma; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Liver Neoplasms; Piperazines; Pyrimidines; Pyrroles; Soft Tissue Neoplasms; Subcutaneous Fat; Sunitinib | 2009 |
Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; DNA Mutational Analysis; Europe; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Piperazines; Practice Guidelines as Topic; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2009 |
In vitro anti-leukaemia activity of pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs).
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Thiazepines | 2010 |
[Treatment of extensive disease].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Long-Term Care; Neoplasm Invasiveness; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2009 |
[Internal medical therapy of gastrointestinal stroma tumors].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Piperazines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2009 |
Neurological adverse effects caused by cytotoxic and targeted therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration | 2009 |
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution | 2009 |
Advances in the treatment of gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Delivery Systems; Drug Resistance, Neoplasm; Drugs, Investigational; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2010 |
[Aspects of surgical treatment for gastro-intestinal stromal tumors].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Diagnostic Imaging; Disease Progression; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Laparoscopy; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2009 |
[Gastrointestinal stromal tumors: evolution of a tumor concept from unclassifiable neoplasms to targeted molecular therapy].
Topics: Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Indoles; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sequence Analysis, DNA; Sunitinib | 2010 |
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Gastrointestinal stromal tumor: a bridge between bench and bedside.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2009 |
Gastrointestinal stromal tumors: current management.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Molecular response prediction in gastrointestinal stromal tumors.
Topics: Animals; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Optimal use of targeted agents for advanced gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Staging; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Survival Rate; Treatment Outcome | 2010 |
[Focus on GIST management].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2010 |
Molecular basis and management of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2010 |
[Treatment with antiangiogenic drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Bevacizumab; Humans; Imatinib Mesylate; Indoles; Neoplasms; Piperazines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
[Multimodality therapy concepts for soft tissue sarcomas].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Cross-Sectional Studies; Gastrointestinal Stromal Tumors; Humans; Hyperthermia, Induced; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Palliative Care; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Radiotherapy, Adjuvant; Sarcoma; Soft Tissue Neoplasms; Sunitinib | 2010 |
Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Models, Economic; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2010 |
[Clinical manifestation of targeted drugs in individualized therapy of malignant tumors].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Doxorubicin; Drug Delivery Systems; ErbB Receptors; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Mutation; Neoplasms; Piperazines; Prednisone; Pyrimidines; Pyrroles; Remission Induction; Rituximab; Sunitinib; Vincristine | 2010 |
Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2011 |
A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST.
Topics: Adult; Angiogenesis Inhibitors; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Delivery Systems; Enzyme Inhibitors; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Neoplasm Staging; Pilot Projects; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis | 2011 |
Added value of molecular targeted agents in oncology.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Biomarkers, Pharmacological; Breast Neoplasms; Female; Humans; Imatinib Mesylate; Indoles; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, ErbB-2; Rituximab; Sunitinib; Trastuzumab | 2011 |
Current and emerging pharmacological treatments for gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Drugs, Investigational; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2011 |
Management of recurrent gastrointestinal stromal tumors.
Topics: Benzamides; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2011 |
Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit.
Topics: Benzamides; Binding Sites; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Stability; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.
Topics: Antineoplastic Agents; Benzamides; Giant Cell Tumors; Humans; Imatinib Mesylate; Indoles; Macrophage Colony-Stimulating Factor; Macrophages; Piperazines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Soft Tissue Neoplasms; Sunitinib; Synovial Membrane; Synovitis, Pigmented Villonodular; Tendons | 2011 |
[Indications and current development of new targeted therapies in pediatric oncology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases | 2011 |
Targeted drug therapies and cancer.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Drug Delivery Systems; Erlotinib Hydrochloride; Gastrointestinal Neoplasms; Gefitinib; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
[Gastrointestinal stromal tumour (GIST): current standards in multimodal management].
Topics: Alleles; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; DNA Mutational Analysis; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Maintenance Chemotherapy; Neoplasm Invasiveness; Neoplasm Staging; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2011 |
Gastrointestinal stromal tumor: advances in diagnosis and management.
Topics: Benzamides; Diagnosis, Differential; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Platelet-Derived Growth Factor; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2011 |
Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
Gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Molecular Targeted Therapy; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2012 |
Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
Topics: Benzamides; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2011 |
Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Thiazoles | 2011 |
Small intestine gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Intestine, Small; Neoadjuvant Therapy; Neoplasm Metastasis; Piperazines; Prognosis; Pyrimidines; Pyrroles; Sunitinib | 2012 |
[Resistance and treatment strategy of gastrointestinal stromal tumor target therapy].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Adjuvant therapy of gastrointestinal stromal tumors.
Topics: Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Current management of gastrointestinal stromal tumors--a comprehensive review.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2012 |
A multidisciplinary approach to giant cell tumors of tendon sheath and synovium--a critical appraisal of literature and treatment proposal.
Topics: Adult; Antineoplastic Agents; Arthroplasty; Arthroscopy; Benzamides; Chemotherapy, Adjuvant; Female; Giant Cell Tumors; Humans; Imatinib Mesylate; Indoles; Interdisciplinary Communication; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Radioisotopes; Radiotherapy, Adjuvant; Sunitinib; Synovectomy; Synovial Membrane; Tendons; Tenosynovitis | 2013 |
FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Blood Glucose; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Multimodal Imaging; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Pyrroles; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Evidence for therapeutic drug monitoring of targeted anticancer therapies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Area Under Curve; Benzamides; Benzenesulfonates; Cetuximab; Dasatinib; Drug Monitoring; Everolimus; Evidence-Based Medicine; Half-Life; Humans; Imatinib Mesylate; Indoles; Injections, Intravenous; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Rituximab; Sirolimus; Sorafenib; Sunitinib; Thiazoles | 2012 |
[Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2013 |
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.
Topics: Animals; Benzamides; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sunitinib | 2013 |
[Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Crown Ethers; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Glucuronosyltransferase; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2013 |
[Oral toxicity of targeted anticancer therapies].
Topics: Angiogenesis Inhibitors; Benzamides; ErbB Receptors; Glossitis, Benign Migratory; Humans; Hyperpigmentation; Imatinib Mesylate; Indoles; Maxillary Diseases; Molecular Targeted Therapy; Mouth Mucosa; Osteonecrosis; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Pyrroles; Radiation Injuries; Radiotherapy; Stomatitis; Stomatitis, Aphthous; Sunitinib; TOR Serine-Threonine Kinases | 2014 |
Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidence; Indoles; Models, Statistical; Piperazines; Prevalence; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rare Diseases; Registries; Sunitinib; Treatment Failure; United Kingdom | 2014 |
Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2014 |
Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Treatment Outcome | 2014 |
[Molecular biology of sarcoma and therapeutic choices].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzamides; Bone Neoplasms; Crizotinib; Denosumab; Dermatofibrosarcoma; Gastrointestinal Stromal Tumors; Gene Amplification; Gene Deletion; Giant Cell Tumor of Bone; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Phenylurea Compounds; Piperazines; Point Mutation; Prognosis; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sarcoma; Sarcoma, Ewing; Sunitinib; Synovitis, Pigmented Villonodular; Translocation, Genetic | 2015 |
Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2015 |
Duodenal gastrointestinal stromal tumor: From clinicopathological features to surgical outcomes.
Topics: Age Distribution; Antineoplastic Agents; Benzamides; Biopsy, Fine-Needle; Endoscopy, Gastrointestinal; Endosonography; Europe; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Mutation; Pancreaticoduodenectomy; Phenylurea Compounds; Piperazines; Prevalence; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sex Distribution; Sunitinib; United States | 2015 |
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sarcoma; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Is sunitinib a Narrow Therapeutic Index Drug? - A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug and Narcotic Control; Drugs, Generic; Humans; Imatinib Mesylate; Indoles; Inhibitory Concentration 50; Neoplasms; Organ Specificity; Phosphorylation; Protein Kinase Inhibitors; Pyrroles; Risk Assessment; Signal Transduction; Sunitinib; Toxicity Tests | 2016 |
Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Digestive System Surgical Procedures; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoadjuvant Therapy; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2016 |
Kinase Inhibitors in Multitargeted Cancer Therapy.
Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2017 |
GEIS guidelines for gastrointestinal sarcomas (GIST).
Topics: Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Sunitinib | 2017 |
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Pyridines; Pyrroles; Sunitinib | 2017 |
Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.
Topics: Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Pyrazoles; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Standard of Care; Triazines | 2020 |
Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade.
Topics: Apoptosis; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Naphthyridines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Triazines; Urea | 2020 |
Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation.
Topics: Binding Sites; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyridines; Pyrroles | 2021 |
Efficacy of post-first-line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta-analysis.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Network Meta-Analysis; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2023 |
32 trial(s) available for pyrroles and imatinib mesylate
| Article | Year |
|---|---|
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Double-Blind Method; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2006 |
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
Topics: Adult; Antineoplastic Agents; Benzamides; Biomarkers; Endothelial Cells; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Monocytes; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Canada; Cost-Benefit Analysis; Cross-Over Studies; Disease-Free Survival; Drug Costs; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Markov Chains; Piperazines; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Sunitinib | 2008 |
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Topics: Adult; Aged; Benzamides; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2008 |
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Salvage Therapy; Sunitinib | 2009 |
Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Health Resources; Humans; Imatinib Mesylate; Indoles; Markov Chains; Models, Econometric; Neoplasm Metastasis; Piperazines; Placebos; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis; Treatment Failure | 2008 |
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2009 |
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Benzamides; Biomarkers, Tumor; Demography; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Japan; Male; Middle Aged; Neoplasm Proteins; Piperazines; Pyrimidines; Pyrroles; Solubility; Sunitinib; Treatment Failure; Young Adult | 2010 |
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
Topics: Adult; Aged; Benzamides; Cell Proliferation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Treatment Failure | 2009 |
Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Calcitriol; Calcium Channel Agonists; Cell Line, Tumor; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Female; Imatinib Mesylate; Indoles; Lomustine; Male; Mastocytoma; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptors, Calcitriol; Skin Neoplasms; Treatment Outcome; Vinblastine | 2010 |
Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Gastrointestinal Stromal Tumors; Humans; Hyperammonemia; Imatinib Mesylate; Indoles; Japan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Portography; Pyrimidines; Pyrroles; Remission Induction; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2011 |
Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Salvage Therapy; Sunitinib; Time Factors; Treatment Outcome | 2011 |
A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices.
Topics: Academic Medical Centers; Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hospitals, Community; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Practice Patterns, Physicians'; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Registries; Sunitinib; United States; Young Adult | 2011 |
Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phthalazines; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sunitinib | 2011 |
Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib.
Topics: Aged; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2012 |
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.
Topics: Adult; Aged; Benzamides; Biomarkers, Tumor; Cross-Over Studies; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neovascularization, Pathologic; Piperazines; Placebos; Pyrimidines; Pyrroles; Retreatment; Sunitinib; Survival Analysis; Young Adult | 2012 |
Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Blood Pressure; Carcinoma, Renal Cell; Child; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hypertension; Imatinib Mesylate; Indoles; Kidney Neoplasms; Male; Middle Aged; Piperazines; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors; Young Adult | 2012 |
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Benzamides; Double-Blind Method; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Survival Rate; Treatment Failure | 2013 |
Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments.
Topics: Adult; Aged; Animals; Benzamides; Cell Division; Dichloroacetic Acid; Disease Models, Animal; Drug Monitoring; Familial Primary Pulmonary Hypertension; Female; Fibroblasts; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gene Expression Profiling; Glycolysis; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Indoles; Lung; Male; Middle Aged; Monocrotaline; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Sunitinib; Young Adult | 2013 |
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzamides; Benzimidazoles; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolones; Sunitinib | 2013 |
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Republic of Korea; Sunitinib; Time Factors; Treatment Outcome | 2013 |
A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Piperazines; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Failure; Tumor Burden; Young Adult | 2014 |
Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Outcome Assessment, Health Care; Phenylurea Compounds; Piperazines; Prospective Studies; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Treatment Failure; World Health Organization | 2014 |
Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Placebo Effect; Pyridines; Pyrroles; Quality of Life; Sunitinib; Treatment Failure | 2015 |
Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Thiazoles; Treatment Failure | 2014 |
Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Double-Blind Method; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Middle Aged; Phenylurea Compounds; Pyridines; Pyrroles; Sunitinib; Survival Analysis; Young Adult | 2015 |
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; France; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Indoles; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2016 |
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Sunitinib | 2016 |
Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retreatment; Sunitinib; Treatment Failure; Treatment Outcome | 2017 |
Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial.
Topics: Antineoplastic Agents; Diarrhea; Double-Blind Method; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Pyrroles | 2022 |
181 other study(ies) available for pyrroles and imatinib mesylate
| Article | Year |
|---|---|
Progress toward virtual screening for drug side effects.
Topics: Adenosine Diphosphate; Algorithms; Azepines; Benzamides; Binding Sites; Computational Biology; Computer Simulation; Drug Delivery Systems; Enzyme Inhibitors; Guanosine Diphosphate; Imatinib Mesylate; Models, Molecular; Piperazines; Protein Binding; Protein Kinases; Pyrimidines; Pyrroles; Receptors, Drug; Receptors, Purinergic P2; Sensitivity and Specificity; Static Electricity | 2002 |
Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.
Topics: Apoptosis; Benzamides; Binding Sites; Cell Division; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia; Models, Molecular; Mutagenesis, Site-Directed; Oncogene Proteins v-abl; Piperazines; Protein Conformation; Pyrazoles; Pyrimidines; Pyrroles; src-Family Kinases | 2003 |
Synthetic lethality: killing cancer with cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzoquinones; Cell Cycle Proteins; DNA-Binding Proteins; E2F Transcription Factors; Gefitinib; Genes, Tumor Suppressor; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mutation; Neoplasms; Phosphoric Monoester Hydrolases; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Signal Transduction; Sirolimus; Transcription Factors; Tumor Suppressor Proteins | 2002 |
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Small Cell; Cell Division; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Mice; Mice, Nude; Phosphorylation; Phosphotyrosine; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Stem Cell Factor; Sunitinib; Tumor Cells, Cultured | 2003 |
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.
Topics: Adult; Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Benzamides; Blotting, Western; Cell Division; Cell Line; Cell Survival; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Eosinophils; Gene Deletion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Indoles; Male; Mice; Models, Chemical; Models, Genetic; Molecular Sequence Data; Peptides; Phthalazines; Piperazines; Precipitin Tests; Protein Structure, Tertiary; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Recombinant Fusion Proteins; Recurrence; Tyrosine | 2003 |
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Topics: Animals; Benzamides; Burkitt Lymphoma; Cell Division; Drug Therapy, Combination; Enzyme Activation; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-hck; Pyrimidines; Pyrroles; src-Family Kinases | 2004 |
Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Neoplasms; Cell Division; Enzyme Inhibitors; ErbB Receptors; Humans; Imatinib Mesylate; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Prostatic Neoplasms; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Substrate Specificity; Xenograft Model Antitumor Assays | 2004 |
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Topics: Adenoma, Islet Cell; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Clinical Protocols; Cyclophosphamide; Disease Models, Animal; Endothelial Cells; Imatinib Mesylate; Indoles; Mice; Mice, Transgenic; Neovascularization, Pathologic; Pancreatic Neoplasms; Pericytes; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Remission Induction; Sunitinib | 2005 |
Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Inhibitory Concentration 50; Lactams, Macrocyclic; Piperazines; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Sarcoma, Synovial; Trastuzumab | 2005 |
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib; Tumor Cells, Cultured | 2006 |
Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Doxorubicin; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2006 |
Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine.
Topics: Aged; Benzamides; Drug Interactions; Female; Humans; Hypothyroidism; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Thyroid Function Tests; Thyrotropin; Thyroxine | 2006 |
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Topics: Angiogenesis Inducing Agents; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; HT29 Cells; Humans; Imatinib Mesylate; Indoles; Mice; Mice, Inbred Strains; Piperazines; Propionates; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Screening Assays, Antitumor; G1 Phase; Humans; Imatinib Mesylate; Phosphorylation; Piperazines; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Sarcoma, Ewing; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Vincristine | 2006 |
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinib-resistant.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Bone Marrow Cells; Caspase 3; Caspase 8; Caspase 9; Caspases; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Thiazepines; Tumor Cells, Cultured | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Sunitinib for imatinib-resistant GIST.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Multicenter Studies as Topic; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2006 |
Current and future management of GIST.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Benzoquinones; Disease Progression; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2006 |
Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; Erythroblasts; Extracellular Signal-Regulated MAP Kinases; Humans; Imatinib Mesylate; Indoles; Mice; Mice, Transgenic; Mutation; Oncogene Protein v-akt; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; STAT3 Transcription Factor; Stem Cell Factor | 2007 |
STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
Topics: Apoptosis; bcl-X Protein; Benzamides; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myeloid; Microtubules; Monocytes; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oxazepines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Pyrroles | 2007 |
Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2007 |
[Imatinib . Sunitinib].
Topics: Angiogenesis Inhibitors; Benzamides; Carcinoma, Renal Cell; Dermatofibrosarcoma; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Neoplasms; Sunitinib; Survival Rate | 2007 |
Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2008 |
[Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; ErbB Receptors; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Hypothyroidism; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2007 |
Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit.
Topics: Aged; Aged, 80 and over; Benzamides; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Male; Middle Aged; Mutation; Neoplasms, Unknown Primary; Piperazines; Polymorphism, Genetic; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib | 2008 |
Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070.
Topics: 14-3-3 Proteins; Amino Acid Sequence; Antineoplastic Agents; Apoptosis; Benzamides; Butadienes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Forkhead Box Protein O3; Forkhead Transcription Factors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indoles; Intracellular Signaling Peptides and Proteins; K562 Cells; Molecular Sequence Data; Mutation, Missense; Neoplasm Proteins; Nitriles; Peptides; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recombinant Fusion Proteins; Signal Transduction; Sirolimus | 2008 |
Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2008 |
Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Amplification; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; src-Family Kinases | 2008 |
[Consensus on the medical treatment of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2007 |
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib | 2008 |
A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Female; Gastrointestinal Stromal Tumors; Health Care Costs; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2008 |
PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Topics: Antigens, CD; Antigens, CD34; Antineoplastic Agents; Apoptosis; Aurora Kinase B; Aurora Kinases; Benzamides; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrroles | 2008 |
Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; Gastrointestinal Stromal Tumors; Gene Amplification; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinase Kinases; Mutation; Piperazines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptor, Platelet-Derived Growth Factor alpha; RNA, Small Interfering; Signal Transduction | 2008 |
Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2008 |
Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.
Topics: Adenosine Triphosphate; Animals; Benzamides; Benzenesulfonates; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Electron Transport; Galactose; Glucose; Imatinib Mesylate; Indoles; Male; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocytes, Cardiac; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Sorafenib; Sunitinib; Thiazoles | 2008 |
A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; In Vitro Techniques; Piperazines; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Sarcoma, Ewing | 2008 |
Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Perforation; Male; Neoplasm Recurrence, Local; Peritonitis; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2008 |
Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype.
Topics: Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2008 |
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Biological Transport; Cell Line, Transformed; Cell Line, Tumor; Humans; Hydrolysis; Imatinib Mesylate; Indoles; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Photoaffinity Labels; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2009 |
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.
Topics: Animals; Antineoplastic Agents; Benzamides; Blood Glucose; Diabetes Mellitus, Type 1; Female; Humans; Imatinib Mesylate; Indoles; Leukocytes; Mice; Mice, Inbred NOD; Mice, SCID; Pancreas; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Sunitinib | 2008 |
Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature.
Topics: Animals; Benzamides; Benzenesulfonates; Cell Line, Tumor; Extravasation of Diagnostic and Therapeutic Materials; Humans; Imatinib Mesylate; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptors, Transforming Growth Factor beta; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2009 |
Imatinib-induced interstitial lung disease and sunitinib-associated intra-tumour haemorrhage.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Hemorrhage; Humans; Imatinib Mesylate; Indoles; Lung Diseases, Interstitial; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2008 |
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Phosphorylation; Piperazines; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Spectrometry, Fluorescence; Sunitinib | 2009 |
Hits and misses in targeting pediatric cancers.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Infant; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2009 |
Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Controversies in the surgical management of GIST in the era of imatinib.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Piperazines; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib; Survival Rate; Treatment Failure; Treatment Outcome | 2009 |
New paradigms in gastrointestinal stromal tumour management.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Patient Selection; Piperazines; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Young Adult | 2009 |
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2009 |
Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors.
Topics: Acute Disease; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Chemical and Drug Induced Liver Injury; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Liver; Liver Failure; Middle Aged; Peritoneal Neoplasms; Piperazines; Prednisolone; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Perfusion patterns of metastatic gastrointestinal stromal tumor lesions under specific molecular therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiography; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Perfusion Imaging; Pilot Projects; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Solubility; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Biochemical and pathological response of prostate cancer in a patient with metastatic renal cell carcinoma on sunitinib treatment.
Topics: Benzamides; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kidney Neoplasms; Male; Middle Aged; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Benzamides; Female; Forkhead Transcription Factors; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Indoles; Interleukin-10; Intestinal Neoplasms; Macrophages; Male; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptors, Cell Surface; Sunitinib; T-Lymphocytes, Regulatory | 2010 |
Tyrosine kinase inhibitor-induced macrocytosis.
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2009 |
Drug binding and resistance mechanism of KIT tyrosine kinase revealed by hydrogen/deuterium exchange FTICR mass spectrometry.
Topics: Amino Acid Substitution; Benzamides; Binding Sites; Deuterium Exchange Measurement; Drug Resistance; Imatinib Mesylate; Indoles; Mass Spectrometry; Molecular Sequence Data; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance.
Topics: Amino Acid Substitution; Antineoplastic Agents; Benzamides; Catalytic Domain; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Humans; Imatinib Mesylate; Indoles; Kinetics; Microchemistry; Models, Biological; Mutant Proteins; Peptide Mapping; Phosphorylation; Phosphotyrosine; Piperazines; Protein Binding; Protein Interaction Domains and Motifs; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Recombinant Fusion Proteins; Sunitinib | 2010 |
Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
Topics: Benzamides; Binding Sites; Carbazoles; Computer Simulation; Dasatinib; Drug Design; Furans; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Staurosporine; Sunitinib; Thiazoles | 2010 |
Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Flavonoids; Humans; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubule-Associated Proteins; Oxazepines; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Survivin | 2010 |
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Diagnostic Imaging; DNA Mutational Analysis; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Humans; Imatinib Mesylate; Indoles; Piperazines; Prognosis; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.
Topics: Aged; Benzamides; Chemotherapy, Adjuvant; Disease Progression; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation, Missense; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sequence Deletion; Sunitinib; Survival Analysis; Tomography, X-Ray Computed | 2010 |
Acne rosacea associated imatinib mesylate in a gastrointestinal stromal tumor patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Biopsy; Gastrointestinal Stromal Tumors; Histamine Antagonists; Humans; Hyperpigmentation; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Keratoderma, Palmoplantar; Liver Neoplasms; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Rosacea; Skin; Skin Pigmentation; Sunitinib; Treatment Outcome | 2011 |
Current management of GISTs.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2010 |
[Efficacy of tyrosine kinase inhibitor therapy combined with surgical resection in patients with metastatic gastrointestinal stromal tumor].
Topics: Adult; Aged; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intraoperative Period; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome | 2010 |
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Topics: Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blood Glucose; Dasatinib; Diabetes Mellitus; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Imatinib Mesylate; Indoles; Linear Models; Male; Middle Aged; Neoplasms; Niacinamide; Pennsylvania; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thiazoles; Time Factors; Treatment Outcome | 2011 |
A novel primary KIT exon 9 single nucleotide substitution c.1427G>T (p.Ser476Ile) in a gastrointestinal stromal tumor.
Topics: Adult; Antineoplastic Agents; Base Sequence; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Disease Progression; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Molecular Sequence Data; Peritoneal Neoplasms; Piperazines; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biological Availability; Compassionate Use Trials; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Half-Life; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Staging; Piperazines; Protease Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis | 2011 |
[The role of pathologists in the target therapy of gastrointestinal tumors].
Topics: Anoctamin-1; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chloride Channels; Drug Delivery Systems; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Membrane Proteins; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; Chi-Square Distribution; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Exons; Female; Gastrointestinal Stromal Tumors; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Mutation; Phenotype; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sunitinib; Time Factors; Treatment Failure | 2012 |
Cyclooxygenase-2 expression in gastrointestinal stromal tumours.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chi-Square Distribution; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Male; Middle Aged; Mitosis; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Tumor Burden | 2010 |
[Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
Topics: Adult; Benzamides; Benzenesulfonates; Carcinoma, Renal Cell; Choristoma; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Imatinib Mesylate; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Pleural Diseases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thymus Gland; Thyroxine | 2011 |
Mutational spectrum and therapy response of metastasized GIST in Central Switzerland - a population-based study.
Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Benzamides; Disease Progression; DNA Mutational Analysis; DNA Primers; Exons; Female; Gastrointestinal Stromal Tumors; Genetics, Population; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Switzerland | 2011 |
Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Radiography; Sunitinib | 2011 |
Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Treatment Failure | 2011 |
[Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Recurrence; Sunitinib | 2011 |
[A case of imatinib-resistant GIST treated by sunitinib].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Quality of Life; Sunitinib; Tomography, X-Ray Computed | 2011 |
[KIT and KIT: from biology to clinical use].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2012 |
[Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Salvage Therapy; Sunitinib | 2011 |
The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Stem Cell Factor; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzoquinones; Cell Growth Processes; Cell Line, Tumor; Female; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
Topics: Animals; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Indazoles; Indoles; Kinetics; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib; Spodoptera; Staurosporine; Sulfonamides; Sunitinib; Surface Plasmon Resonance; Thiazoles; Transfection | 2012 |
Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Mitosis; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survivin; Treatment Outcome | 2011 |
Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport.
Topics: Animals; Benzamides; Binding, Competitive; Biological Transport; Cells, Cultured; Clinical Trials as Topic; Dogs; Down-Regulation; Drug Evaluation, Preclinical; Humans; Imatinib Mesylate; Indoles; Iodine Radioisotopes; Monocarboxylic Acid Transporters; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Symporters; Thyroxine; Transfection; Triiodothyronine | 2012 |
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Risk Factors; Serum Albumin; Sorafenib; Sunitinib; Survival Rate; Young Adult | 2012 |
Gastrointestinal stromal tumors of the stomach.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Gastroscopy; Humans; Imatinib Mesylate; Indoles; Laparoscopy; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Radiotherapy, Adjuvant; Stomach Neoplasms; Sunitinib | 2012 |
[Twenty-one-year survival case of rectal GIST treated with combined therapies].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Pyrroles; Rectal Neoplasms; Recurrence; Sunitinib; Time Factors | 2011 |
[A case of gastrointestinal stromal tumor (GIST) successfully treated with resection after a long-term control medication by molecular targeted drugs].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2011 |
Sorafenib: muscle wasting.
Topics: Benzamides; Benzenesulfonates; Humans; Imatinib Mesylate; Indoles; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Rhabdomyolysis; Sorafenib; Sunitinib | 2011 |
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Crizotinib; Epithelial-Mesenchymal Transition; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Metastasis; Niacinamide; Pericytes; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Tumor Cells, Cultured | 2012 |
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Benzenesulfonates; Carcinoid Tumor; Carcinoma, Squamous Cell; CD5 Antigens; DNA Mutational Analysis; Enzyme Activation; Female; Genetic Association Studies; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation, Missense; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thymoma; Thymus Neoplasms; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins | 2012 |
Intracranial metastasis from pediatric GI stromal tumor.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Brain Neoplasms; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Stomach Neoplasms; Sunitinib; Treatment Outcome | 2012 |
Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2012 |
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Multivariate Analysis; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2012 |
Topical psoralen plus UV-A therapy for tyrosine kinase inhibitor-induced hand-foot syndrome.
Topics: Benzamides; Female; Hand-Foot Syndrome; Humans; Imatinib Mesylate; Indoles; Male; Piperazines; Protein Kinase Inhibitors; PUVA Therapy; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Imatinib Mesylate; In Vitro Techniques; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Asian People; Benzamides; China; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2012 |
Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Disease Progression; Feasibility Studies; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Young Adult | 2012 |
Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Minnesota; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib | 2012 |
Lab reports and cat scans: can veterinary oncology guide our way to new treatments for human cancers?
Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cats; Disease Models, Animal; Dogs; Female; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mast-Cell Sarcoma; Neoplasms; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Thiazoles; Transcriptome | 2012 |
[Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2012 |
[Responses to treatment and switching tyrosine kinase inhibitors in gastrointestinal stromal tumor(GIST)].
Topics: Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression.
Topics: Animals; Benzamides; Disease Models, Animal; Hemodynamics; Hypertension, Pulmonary; Hypoxia; Imatinib Mesylate; Indoles; Mice; Mice, Knockout; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Serotonin; Tryptophan Hydroxylase | 2013 |
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Evaluation of regorafenib in colorectal cancer and GIST.
Topics: Antineoplastic Agents; Benzamides; Colorectal Neoplasms; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sunitinib | 2013 |
Drugmakers struggle with Indian patents.
Topics: Antineoplastic Agents; Benzamides; Drug Design; Drug Industry; Humans; Imatinib Mesylate; India; Indoles; Niacinamide; Patents as Topic; Phenylurea Compounds; Piperazines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib | 2012 |
Establishment and characterization of a novel xenograft model of human gastrointestinal stromal tumor in mice.
Topics: Aged; Animals; Benzamides; Disease Models, Animal; Esophageal Neoplasms; Exons; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Indoles; Male; Mice; Molecular Targeted Therapy; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Transplantation, Heterologous | 2013 |
[A case of drug resistant recurrent gastrointestinal stromal tumor treated surgically by resection, partial hepatectomy and diaphragmectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Diaphragm; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Jejunal Neoplasms; Liver Neoplasms; Male; Peritoneal Neoplasms; Piperazines; Pyrimidines; Pyrroles; Recurrence; Sunitinib | 2012 |
ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sunitinib | 2012 |
ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Benzamides; Cell Adhesion Molecules; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Library; Genetic Loci; Humans; Imatinib Mesylate; Indoles; Phosphoproteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; RNA, Small Interfering; Sunitinib; Transforming Growth Factor beta3; Zinc Fingers | 2013 |
When a thymic carcinoma "becomes" a GIST.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Thymoma; Thymus Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents; Asian People; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Sequence Data; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl.
Topics: Benzamides; Cell Membrane; Cell Survival; Cells, Cultured; Green Fluorescent Proteins; HEK293 Cells; Humans; Imatinib Mesylate; Indoles; Insulin; Phosphatidylinositol 3-Kinases; Phosphatidylinositol Phosphates; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphoric Monoester Hydrolases; Phosphorylation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib; Time Factors | 2013 |
Gastrointestinal stromal tumors: diagnosis, therapy and follow-up care in Austria.
Topics: Adult; Aftercare; Austria; Benzamides; Biopsy; Child; Combined Modality Therapy; Cooperative Behavior; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; Endoscopy, Gastrointestinal; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Indoles; Interdisciplinary Communication; Mitotic Index; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Nomograms; Palliative Care; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sunitinib | 2013 |
[Gastrointestinal stromal tumor (GIST)--tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2012 |
[Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
Topics: Adult; Aged; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.
Topics: Amino Acid Motifs; Animals; Antineoplastic Agents; Benzamides; Chlorocebus aethiops; COS Cells; Dasatinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Molecular Docking Simulation; Mutation, Missense; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Thiazoles | 2013 |
Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2013 |
Screening assay for blood vessel maturation inhibitors.
Topics: Actins; Angiogenesis Inhibitors; Animals; Benzamides; Blood Vessels; Cell Line; Coculture Techniques; Drug Evaluation, Preclinical; Endothelial Cells; Fibroblasts; Green Fluorescent Proteins; HEK293 Cells; Human Umbilical Vein Endothelial Cells; Humans; Imatinib Mesylate; Indoles; Lentivirus; Mice; Muscle, Smooth; Neovascularization, Physiologic; Pericytes; Piperazines; Promoter Regions, Genetic; Pyrimidines; Pyrroles; Stem Cells; Sunitinib | 2013 |
Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor.
Topics: Aged; Antineoplastic Agents; Exanthema; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2014 |
Rechallenge of drugs in the era of targeted therapy.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2013 |
Proteomic strategy for probing complementary lethality of kinase inhibitors against pancreatic cancer.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Heme Oxygenase-1; Humans; Imatinib Mesylate; Indoles; Pancreatic Neoplasms; Piperazines; Protein Kinase Inhibitors; Proteome; Pyrimidines; Pyrroles; Spectrometry, Mass, Electrospray Ionization; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Indoles; Interleukin-3; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Random Allocation; Sunitinib | 2014 |
Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Topics: Aged; Antineoplastic Agents; Benzamides; Body Weight; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Erlotinib Hydrochloride; Female; Gastric Acid; Half-Life; Histamine H2 Antagonists; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasms; Outpatients; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Tandem Mass Spectrometry | 2014 |
[A case of imatinib-resistant gastrointestinal stromal tumor treated with low-dose sunitinib].
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Intestine, Small; Male; Peritoneal Neoplasms; Piperazines; Pyrimidines; Pyrroles; Recurrence; Salvage Therapy; Sunitinib | 2013 |
Diarylureas and diarylamides with pyrrolo[2,3-d]pyrimidine scaffold as broad-spectrum anticancer agents.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Niacinamide; Phenylurea Compounds; Piperazines; Pyrimidines; Pyrroles; Sorafenib | 2014 |
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.
Topics: Animals; Axitinib; Benzamides; Erlotinib Hydrochloride; Female; HeLa Cells; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lapatinib; Mice; Morpholines; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Trypanosomiasis, African | 2014 |
Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzamides; Biopsy; Cell Survival; Disease Models, Animal; Drug Evaluation, Preclinical; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Mice, Knockout; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Tumor Burden | 2014 |
Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Humans; Imatinib Mesylate; Macrophages; Mice; Mice, Inbred ICR; Mice, SCID; Neurilemmoma; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sirolimus; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Silencing; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; MAP Kinase Signaling System; Melanoma; Mice; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; RNA, Small Interfering; Sulfonamides; Sunitinib; Up-Regulation; Vemurafenib | 2014 |
[Treatment strategy for recurrent and metastatic gastrointestinal stromal tumors].
Topics: Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indazoles; Indoles; Liver Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Recurrence; Sulfonamides; Sunitinib | 2014 |
[Drug resistance mechanism and new therapy strategy progression in targeted treatment of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Quality of Life; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2014 |
Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.
Topics: Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dasatinib; Hep G2 Cells; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Sunitinib; Thiazoles | 2014 |
Gastrointestinal stromal tumors, version 2.2014.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2014 |
Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Drug Substitution; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Retreatment; Sunitinib; Treatment Outcome; Young Adult | 2014 |
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Imidazoles; Indoles; Inhibitory Concentration 50; Models, Molecular; Molecular Conformation; Mutation; Neoplasm Recurrence, Local; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridazines; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Hepatic artery embolization for liver metastasis of gastrointestinal stromal tumor following imatinib and sunitinib therapy.
Topics: Adult; Aged; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Embolization, Therapeutic; Female; Gastrointestinal Stromal Tumors; Hepatic Artery; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2014 |
[Adverse effects of Sutent(®): pseudoporphyria and scrotal necrosis].
Topics: Antineoplastic Agents; Blister; Genital Diseases, Male; Humans; Imatinib Mesylate; Indoles; Male; Necrosis; Neoplasm Proteins; Photosensitivity Disorders; Protein Kinase Inhibitors; Pyrroles; Scrotum; Sunitinib | 2014 |
[The importance of mutational status in prognosis and therapy of GIST].
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Phenylurea Compounds; Piperazines; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sensitivity and Specificity; Sunitinib | 2015 |
[A case of recurrent duodenal gastrointestinal stromal tumor resistant to imatinib and sunitinib, successfully treated with regorafenib].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Duodenal Neoplasms; Fatal Outcome; Female; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Middle Aged; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Recurrence; Sunitinib; Treatment Outcome | 2014 |
[A case of small intestinal gastrointestinal stromal tumor (GIST) with peritoneal dissemination, treated effectively with molecular target drug after operation].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Molecular Targeted Therapy; Peritoneal Neoplasms; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2014 |
Primary gastrointestinal stromal tumor of the liver treated with sequential therapy.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; DNA Mutational Analysis; Drug Substitution; Female; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Liver Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Czech Republic; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Time Factors | 2015 |
Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Topics: Anilides; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Inhibitory Concentration 50; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Piperazines; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Infectious disease. Combating emerging viral threats.
Topics: Adenine; Adenosine; Antiviral Agents; Benzamides; Chloroquine; Communicable Diseases, Emerging; Cyclosporins; Cytosine; Dengue; Drug Approval; Drug Design; Erlotinib Hydrochloride; Hemorrhagic Fever, Ebola; Humans; Imatinib Mesylate; Indoles; Organophosphonates; Piperazines; Purine Nucleosides; Pyrimidines; Pyrroles; Pyrrolidines; Quinazolines; Sunitinib; Viruses | 2015 |
[Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments].
Topics: Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Benzamides; Humans; Imatinib Mesylate; Indoles; Neovascularization, Pathologic; Paraganglioma; Pheochromocytoma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Thalidomide | 2015 |
[Clinical management of advanced gastrointestinal stromal tumors after failure of at least both imatinib and sunitinib targeted therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Pyrroles; Sunitinib | 2015 |
VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Survival; Contrast Media; Drug Monitoring; Female; Imatinib Mesylate; Indoles; Mice; Mice, Inbred BALB C; Molecular Imaging; Neoplasms, Experimental; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Treatment Outcome; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; Retrospective Studies; Sunitinib; Time Factors | 2016 |
The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Chaperonins; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Myeloid Cell Leukemia Sequence 1 Protein; Oxazepines; Proto-Oncogene Proteins c-kit; Pyrroles; Signal Transduction; Treatment Outcome | 2016 |
[A case of a gastrointestinal stromal tumor of the rectum effectively treated with continuously-administered regorafenib after failure of imatinib and sunitinib].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrroles; Rectal Neoplasms; Sunitinib | 2016 |
Detection and Quantification of KIT Mutations in ctDNA by Plasma Safe-SeqS.
Topics: Antineoplastic Agents; DNA Mutational Analysis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Outcome Assessment, Health Care; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Reproducibility of Results; Sunitinib | 2016 |
Computed tomography features and predictive findings of ruptured gastrointestinal stromal tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hematoma; Hemoperitoneum; Humans; Imatinib Mesylate; Indoles; Intestine, Small; Male; Middle Aged; Necrosis; Peritonitis; Pyrroles; Rupture, Spontaneous; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Young Adult | 2017 |
An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Demography; Disease Progression; Female; Gastrointestinal Stromal Tumors; Genetic Association Studies; Genetic Predisposition to Disease; Haplotypes; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Time Factors; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3; Young Adult | 2017 |
[Changes of diagnosis and treatment for gastrointestinal stromal tumors during a 18-year period in four medical centers of China].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; China; Combined Modality Therapy; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-kit; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Young Adult | 2016 |
Gastrointestinal stromal tumours (GISTs): A descriptive study on 29 cases.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Proto-Oncogene Proteins c-kit; Pyrroles; Retrospective Studies; Stomach Neoplasms; Sunitinib; Survival Rate; Tumor Burden; Weight Loss | 2016 |
Gastrointestinal stromal tumor of the stomach with axillary lymph node metastasis: A case report.
Topics: Aged; Axilla; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Metastasis; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Pyrroles; Stomach Neoplasms; Sunitinib; Tomography, X-Ray Computed | 2017 |
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chordoma; Erlotinib Hydrochloride; Female; France; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Skull Base Neoplasms; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2017 |
PDGF-BB/KLF4/VEGF Signaling Axis in Pulmonary Artery Endothelial Cell Angiogenesis.
Topics: Animals; Becaplermin; Cell Hypoxia; Cell Movement; Cell Proliferation; Endothelial Cells; G1 Phase Cell Cycle Checkpoints; Imatinib Mesylate; Indoles; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lung; Male; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar; RNA Interference; Signal Transduction; Sunitinib; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Remodeling | 2017 |
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chromatography, High Pressure Liquid; Drug Monitoring; Feasibility Studies; Female; Humans; Imatinib Mesylate; Indazoles; Indoles; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Tandem Mass Spectrometry; Treatment Outcome; Young Adult | 2017 |
Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Imatinib Mesylate; Indoles; Male; Monocrotaline; Nestin; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pulmonary Artery; Pyrroles; Rats, Wistar; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Remodeling; Ventricular Function, Right; Ventricular Remodeling | 2018 |
Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.
Topics: Adolescent; Antineoplastic Agents; Child; Europe; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome; United States; Young Adult | 2017 |
Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Calcitriol; Carcinoma, Non-Small-Cell Lung; Cholecalciferol; Cisplatin; Cytostatic Agents; Dihydroxycholecalciferols; Docetaxel; Female; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Mice, SCID; Proto-Oncogene Proteins c-sis; Pyrroles; Sunitinib; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2018 |
[Treatment of Regorafenib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib].
Topics: Adult; Aged; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrroles; Sunitinib | 2018 |
[A Long-Term Survivor Who Are Responding to Sunitinib Treatment for Recurrent Imatinib-Resistant Gastrointestinal Stromal Tumor(GIST)of the Stomach].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Pyrroles; Recurrence; Stomach Neoplasms; Sunitinib; Time Factors | 2017 |
Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Humans; Imatinib Mesylate; Janus Kinase 3; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperidines; Pyrimidines; Pyrroles; Signal Transduction | 2018 |
[A Case of Long-Term Survival of Metastatic and Recurrent Duodenal Gastrointestinal Stromal Tumor Treated with Multimodality Managements].
Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Resistance, Neoplasm; Duodenal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Pyrroles; Sunitinib | 2018 |
MRI in predicting the response of gastrointestinal stromal tumor to targeted therapy: a patient-based multi-parameter study.
Topics: Adult; Aged; Diffusion Magnetic Resonance Imaging; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2018 |
Design, synthesis and in vitro apoptotic mechanism of novel pyrrolopyrimidine derivatives.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 9; Cell Line, Tumor; Drug Design; Humans; Imatinib Mesylate; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Pyrroles | 2019 |
Ethyl-2-amino-pyrrole-3-carboxylates are active against imatinib-resistant gastrointestinal stromal tumors in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboxylic Acids; Cell Proliferation; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; In Vitro Techniques; Mice; Mice, Nude; Pyrroles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Poland; Protein Kinase Inhibitors; Public Health Practice; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2019 |
Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cyclin D2; Drug Resistance, Neoplasm; Drug Synergism; Glycogen Synthase Kinase 3; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leupeptins; Macrocyclic Compounds; Myeloid Cell Leukemia Sequence 1 Protein; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Protein Phosphatase 2; Proteolysis; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyridazines; Pyrroles; Signal Transduction; Wortmannin | 2020 |
[Current status and progress in novel drug research for gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Naphthyridines; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Triazines; Urea | 2020 |
Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
Topics: Antineoplastic Agents; Budgets; Cost-Benefit Analysis; Formularies as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Managed Care Programs; Medicaid; Medicare; Molecular Diagnostic Techniques; Phenylurea Compounds; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sulfonamides; Sunitinib; Treatment Failure; Triazines; United States | 2020 |
Receptor tyrosine kinase inhibitors negatively impact on pro-reparative characteristics of human cardiac progenitor cells.
Topics: Animals; Humans; Imatinib Mesylate; Indoles; Protein Kinase Inhibitors; Pyrroles; Rats; Sorafenib; Stem Cells; Sunitinib | 2022 |
Sunitinib therapy for imatinib-resistant and/or intolerant gastrointestinal stromal tumors: comparison of safety and efficacy between standard and reduced dosage regimens.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2023 |